{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=90&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Orlando",
      "page": 90
    },
    "page_size": 10
  },
  "pagination": {
    "page": 90,
    "page_size": 10,
    "total_count": 6881,
    "total_pages": 689,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=91&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=89&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T15:15:19.810Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02574455",
      "title": "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 529,
      "start_date": "2017-11-07",
      "completion_date": "2020-12-08",
      "has_results": true,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 185,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 144 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574455"
    },
    {
      "nct_id": "NCT04221815",
      "title": "IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Eagle Eye Platinum digital IVUS catheter with optional SyncVision",
          "type": "DEVICE"
        },
        {
          "name": "Resolute Onyx Drug Eluting Stent",
          "type": "DEVICE"
        },
        {
          "name": "Onyx Frontier Drug Eluting Stent",
          "type": "DEVICE"
        },
        {
          "name": "Onyx TruStar Drug Eluting Stent",
          "type": "DEVICE"
        },
        {
          "name": "Onyx TruCor Drug Eluting Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3100,
      "start_date": "2020-10-14",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 40,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 36 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04221815"
    },
    {
      "nct_id": "NCT03272347",
      "title": "Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Islatravir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Islatravir",
          "type": "DRUG"
        },
        {
          "name": "Doravirine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Doravirine",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Doravirine/Islatravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2017-11-27",
      "completion_date": "2022-03-09",
      "has_results": true,
      "last_update_posted_date": "2023-03-29",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03272347"
    },
    {
      "nct_id": "NCT02352948",
      "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non - Small Cell Lung Cancer NSCLC"
      ],
      "interventions": [
        {
          "name": "MEDI4736 (durvalumab)",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)",
          "type": "DRUG"
        },
        {
          "name": "tremelimumab (anti-CTLA4)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 597,
      "start_date": "2015-01-13",
      "completion_date": "2023-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 33,
      "location_summary": "Chandler, Arizona • Anaheim, California • Duarte, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02352948"
    },
    {
      "nct_id": "NCT04955626",
      "title": "To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "BNT162b2 OMI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination BNT162b2 and BNT162b2 OMI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination (Bivalent) BNT162b2 and BNT162b2 OMI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 16372,
      "start_date": "2021-07-01",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 139,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chinle",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04955626"
    },
    {
      "nct_id": "NCT04752215",
      "title": "A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms"
      ],
      "interventions": [
        {
          "name": "BI 765049",
          "type": "DRUG"
        },
        {
          "name": "ezabenlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2021-05-18",
      "completion_date": "2024-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752215"
    },
    {
      "nct_id": "NCT00931840",
      "title": "A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "EZN-2208, Cetuximab and Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enzon Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2009-06",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2011-09-20",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 35,
      "location_summary": "Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931840"
    },
    {
      "nct_id": "NCT07293650",
      "title": "PREcision MEDicine In Achalasia (PREMEDIA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type I Achalasia",
        "Type II Achalasia",
        "EGJ Outflow Obstruction Without Spastic/Hypercontractile Features"
      ],
      "interventions": [
        {
          "name": "Standard Myotomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Tailored Short Myotomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2026-04-29",
      "completion_date": "2032-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 16,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07293650"
    },
    {
      "nct_id": "NCT04707313",
      "title": "A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Placebo (Cohorts 1 and 2)",
          "type": "DRUG"
        },
        {
          "name": "PF-06882961 (Cohorts 1 and 2)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Cohort 3)",
          "type": "DRUG"
        },
        {
          "name": "PF-06882961 (Cohort 3)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 628,
      "start_date": "2021-01-29",
      "completion_date": "2023-10-11",
      "has_results": true,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 27,
      "location_summary": "Anniston, Alabama • Anaheim, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04707313"
    },
    {
      "nct_id": "NCT03337724",
      "title": "A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 579,
      "start_date": "2018-01-06",
      "completion_date": "2023-01-04",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-11-20T15:15:19.810Z",
      "location_count": 28,
      "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 20 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03337724"
    }
  ]
}